Voyager Therapeutics, Inc. (VYGR) SEC Filings & Earnings Calls

Need for additional funding

“We will need to obtain substantial additional funding in connection with our continuing operations.” · word for word

Clinical trial risk

“Identifying potential product candidates and conducting preclinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete.” · word for word

Dependence on collaborations

“We do not have any committed external source of funds other than the amounts we are entitled to receive from our collaboration partners” · word for word

Clinical trial risk: VY7523 and VY1706 are in early stages; data expected Q4 2026.

“VY7523 tau PET imaging data expected Q4 2026; VY1706 dosing expected to begin Q4 2026.”

Dependence on collaboration revenue; collaboration revenue declined 38.5%.

“Collaboration revenue decreased to $3.2M from $5.2M due to transition beyond research phase.”

Clinical development risks remain; positive preclinical data may not translate to human trials.

“Forward-looking statements caution about risks inherent in drug development, including clinical trial outcomes and regulatory decisions.”

Clinical development risks; early-stage trial with uncertain outcomes.

“Forward-looking statements highlight risks inherent in development of product candidates.”

Revenue concentration on collaboration partners; declining collaboration revenue.

“Collaboration revenue decreased 60% YoY to $2.6M.”

Pre-revenue biotech with no approved products; pipeline execution risk.

“Company has no commercial products; all programs are preclinical or clinical.”

Need for substantial additional funding

“Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations.” · word for word

Dependence on collaboration agreements for revenue

“Collaboration revenue was $2.6 million and $6.5 million for the three months ended March 31, 2026 and 2025, respectively.” · word for word

Significant shareholder dilution risk from authorized share increase

“To approve an amendment to the Fifth Amended and Restated Certificate of Incorporation of Voyager Therapeutics, Inc. to increase the number of authorized shares of the Company's capital stock from 125,000,000 shares to 245,000,000 shares and increase the number of authorized shares of common stock from 120,000,000 shares of common stock to 240,000,000 shares” · word for word

Revenue concentration and decline from Neurocrine collaboration

“During the years ended December 31, 2025, and 2024, we recognized $34.1 million and $60.1 million of revenue, respectively, associated with our collaborations with Neurocrine.” · word for word

Pre-revenue stage with net losses

“Net (loss) income (in thousands) $(119,721) for 2025.”

CFO departure

“Dr. Jorgensen will resign as our Chief Financial Officer effective as of May 8, 2026.” · word for word

CFO departure may cause transition risk; internal appointments mitigate disruption.

“Resignation of CFO; appointment of internal successors.”

Collaboration Termination Risk

“In October 2025, Novartis notified us of its partial termination of the 2022 Novartis Option and License Agreement with respect to one Initial Novartis Target and the Novartis Direct License Target, in each case effective February 1, 2026” · word for word

Dependence on Collaborations

“To date, substantially all of our revenue has been derived from our ongoing collaborations and licensing agreements with Neurocrine, Novartis, and Alexion, and from our prior collaborations with Sanofi Genzyme Corporation, AbbVie Biotechnology Ltd and AbbVie Ireland Unlimited Company.” · word for word

Early Stage Pipeline

“We are early in our development efforts. VY7523, our anti-tau antibody candidate, is in early-stage clinical trials, and all of our other active product candidates, including VY1706, are currently in preclinical development.” · word for word

History of Losses

“We have a history of incurring significant losses and anticipate that we will continue to incur losses for the foreseeable future and may never achieve or maintain consistent profitability.” · word for word

Need for Additional Funding

“We will need to raise additional funding, which may not be available on acceptable terms, or at all.” · word for word

Pre-revenue biotech with significant R&D spend and net losses; reliance on partnership milestones for non-dilutive capital.

“Net loss $119.7M in FY2025; cash runway into 2028 but dependent on milestones.”

Loss of Chief Medical Officer could disrupt clinical development programs, though CEO with medical expertise assumes interim oversight.

“Resignation of Chief Medical Officer effective February 20, 2026. CEO assumes interim clinical responsibilities.”

Revenue decline due to lower collaboration revenue; net loss widened.

“Collaboration revenue down 45.5% YoY; net loss increased to $27.9M from $9.0M.”

Partner program discontinuations may signal reduced future milestone potential.

“Novartis discontinued two discovery-stage programs; rights return to Voyager.”

Dependence on collaboration revenue

“Collaboration revenue decreased significantly due to the absence of a $15.0 million amendment fee recognized in the prior year period.”

Cash burn and need for additional funding

“Net cash used in operating activities was $102.2 million during the nine months ended September 30, 2025, compared to $0.8 million of net cash used in operating activities during the nine months ended September 30, 2024.” · word for word

Clinical trial and regulatory uncertainty

“We may never generate the necessary data or results required to obtain marketing approval and achieve product sales.” · word for word